GlassScriptPhysician profile
Jesus E Carale
NPI 1043236961
$800.80
in general payments reported to CMS, 2019-2025
15 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.98 · 2020: $47.71 · 2021: $149 · 2022: $197 · 2023: $17.04 · 2024: $143 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $328.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $233.38 | 2021-2024 | |
| Janssen Biotech, INC. | $118.22 | 2024-2025 | Tremfya |
| Gilead Sciences, INC. | $97.93 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $59.43 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $53.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.55 | 2024 | Entyvio |
| Intercept Pharmaceuticals, INC. | $32.99 | 2020-2025 | |
| Nestle Healthcare Nutrition INC. | $29.13 | 2022 | |
| Stryker Corporation | $25.47 | 2019 | |
| Mauna Kea Technologies, INC. | $21.10 | 2020 | |
| Depuy Synthes Sales INC. | $17.04 | 2023 | Monovisc, Orthovisc |
| Celgene Corporation | $16.87 | 2024 | Zeposia |
| Merck Sharp & Dohme LLC | $16.55 | 2024 | Bridion |
| Phathom Pharmaceuticals, INC. | $15.17 | 2025 | Voquezna |
| Bioventus LLC | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Carale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.